A citation-based method for searching scientific literature

Wen-Jie Li, Xing-Qing Chen, Ling-Ling Xu, Yuan-Qing Li, Bi-Hui Luo. Cardiovasc Diabetol 2020
Times Cited: 43







List of co-cited articles
318 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
Thomas A Zelniker, Marc P Bonaca, Remo H M Furtado, Ofri Mosenzon, Julia F Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding,[...]. Circulation 2020
126
65

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
48

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
44

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
41

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
34

Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats.
Qingmiao Shao, Lei Meng, Sharen Lee, Gary Tse, Mengqi Gong, Zhiwei Zhang, Jichao Zhao, Yungang Zhao, Guangping Li, Tong Liu. Cardiovasc Diabetol 2019
93
32

Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials.
Victor Okunrintemi, Basem M Mishriky, James R Powell, Doyle M Cummings. Diabetes Obes Metab 2021
27
48

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
30

The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
Ann Wan-Chin Ling, Cze-Ci Chan, Shao-Wei Chen, Yi-Wei Kao, Chien-Ying Huang, Yi-Hsin Chan, Pao-Hsien Chu. Cardiovasc Diabetol 2020
22
54

Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial.
Michael Böhm, Jonathan Slawik, Martina Brueckmann, Michaela Mattheus, Jyothis T George, Anne Pernille Ofstad, Silvio E Inzucchi, David Fitchett, Stefan D Anker, Nikolaus Marx,[...]. Eur J Heart Fail 2020
38
31

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
Hang-Long Li, Gregory Y H Lip, Qi Feng, Yue Fei, Yi-Kei Tse, Mei-Zhen Wu, Qing-Wen Ren, Hung-Fat Tse, Bernard-M Y Cheung, Kai-Hang Yiu. Cardiovasc Diabetol 2021
44
27

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
25

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
25

Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week.
Allen Wang, Jennifer B Green, Jonathan L Halperin, Jonathan P Piccini. J Am Coll Cardiol 2019
113
25

Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials.
Gilson C Fernandes, Amanda Fernandes, Rhanderson Cardoso, Jorge Penalver, Leonardo Knijnik, Raul D Mitrani, Robert J Myerburg, Jeffrey J Goldberger. Heart Rhythm 2021
32
34

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
23

Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Frederik Persson, Thomas Nyström, Marit E Jørgensen, Bendix Carstensen, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Jan W Eriksson, Anna Norhammar,[...]. Diabetes Obes Metab 2018
130
20


Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation.
Rachel R Huxley, Kristian B Filion, Suma Konety, Alvaro Alonso. Am J Cardiol 2011
310
18

Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
Muhammad Shariq Usman, Tariq Jamal Siddiqi, Muhammad Mustafa Memon, Muhammad Shahzeb Khan, Wasiq Faraz Rawasia, Muhammad Talha Ayub, Jayakumar Sreenivasan, Yasmeen Golzar. Eur J Prev Cardiol 2018
70
18

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system.
Benedetta Maria Bonora, Emanuel Raschi, Angelo Avogaro, Gian Paolo Fadini. Cardiovasc Diabetol 2021
18
44

The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study.
Hung-Yi Chen, Jing-Yang Huang, Wun-Zhih Siao, Gwo-Ping Jong. Cardiovasc Diabetol 2020
31
25

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
478
16

Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study.
Shilan Seyed Ahmadi, Ann-Marie Svensson, Aldina Pivodic, Annika Rosengren, Marcus Lind. Cardiovasc Diabetol 2020
34
20

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Deepak L Bhatt, Michael Szarek, P Gabriel Steg, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra,[...]. N Engl J Med 2021
517
16

Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?
Salva R Yurista, Herman H W Silljé, Michiel Rienstra, Rudolf A de Boer, B Daan Westenbrink. Cardiovasc Diabetol 2020
19
31

Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.
Wataru Shimizu, Yoshiaki Kubota, Yu Hoshika, Kosuke Mozawa, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu-Ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano,[...]. Cardiovasc Diabetol 2020
43
13

Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry.
Justin B Echouffo-Tcheugui, Peter Shrader, Laine Thomas, Bernard J Gersh, Peter R Kowey, Kenneth W Mahaffey, Daniel E Singer, Elaine M Hylek, Alan S Go, Eric D Peterson,[...]. J Am Coll Cardiol 2017
76
13



Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin.
Shih-Jie Jhuo, I-Hsin Liu, Wei-Chung Tasi, Te-Wu Chou, Yi-Hsiung Lin, Bin-Nan Wu, Kun-Tai Lee, Wen-Ter Lai. Int J Mol Sci 2021
8
75

Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY).
Rajeev K Pathak, Melissa E Middeldorp, Megan Meredith, Abhinav B Mehta, Rajiv Mahajan, Christopher X Wong, Darragh Twomey, Adrian D Elliott, Jonathan M Kalman, Walter P Abhayaratna,[...]. J Am Coll Cardiol 2015
525
11

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson,[...]. Lancet Diabetes Endocrinol 2017
216
11

SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis.
Man Guo, Jingya Ding, Jingsong Li, Jiying Wang, Ting Zhang, Cuiping Liu, Wei Huang, Yang Long, Chenlin Gao, Yong Xu. Diabetes Obes Metab 2018
41
12

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
379
11

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
J P H Wilding, G Charpentier, P Hollander, G González-Gálvez, C Mathieu, F Vercruysse, K Usiskin, G Law, S Black, W Canovatchel,[...]. Int J Clin Pract 2013
249
11

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF.
David Bode, Lukas Semmler, Paulina Wakula, Niklas Hegemann, Uwe Primessnig, Nicola Beindorff, David Powell, Raphael Dahmen, Hartmut Ruetten, Christian Oeing,[...]. Cardiovasc Diabetol 2021
26
19

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
Zien Zhou, Meg J Jardine, Qiang Li, Brendon L Neuen, Christopher P Cannon, Dick de Zeeuw, Robert Edwards, Adeera Levin, Kenneth W Mahaffey, Vlado Perkovic,[...]. Stroke 2021
21
23

Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin.
Koenraad Philippaert, Subha Kalyaanamoorthy, Mohammad Fatehi, Wentong Long, Shubham Soni, Nikole J Byrne, Amy Barr, Jyoti Singh, Jordan Wong, Taylor Palechuk,[...]. Circulation 2021
41
12

Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model.
Ryo Nishinarita, Shinichi Niwano, Hiroe Niwano, Hironori Nakamura, Daiki Saito, Tetsuro Sato, Gen Matsuura, Yuki Arakawa, Shuhei Kobayashi, Yuki Shirakawa,[...]. J Am Heart Assoc 2021
12
41

Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats.
Ting-I Lee, Yao-Chang Chen, Yung-Kuo Lin, Cheng-Chih Chung, Yen-Yu Lu, Yu-Hsun Kao, Yi-Jen Chen. Int J Mol Sci 2019
44
11

Empagliflozin inhibits Na+ /H+ exchanger activity in human atrial cardiomyocytes.
Maximilian Trum, Johannes Riechel, Simon Lebek, Steffen Pabel, Samuel T Sossalla, Stephan Hirt, Michael Arzt, Lars S Maier, Stefan Wagner. ESC Heart Fail 2020
36
13


Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
Chia-Yu Chang, Yung-Hsin Yeh, Yi-Hsin Chan, Jia-Rou Liu, Shang-Hung Chang, Hsin-Fu Lee, Lung-Sheng Wu, Kun-Chi Yen, Chi-Tai Kuo, Lai-Chu See. Cardiovasc Diabetol 2017
30
16

Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes.
Julian Mustroph, Olivia Wagemann, Charlotte M Lücht, Maximilian Trum, Karin P Hammer, Can Martin Sag, Simon Lebek, Daniel Tarnowski, Jörg Reinders, Filippo Perbellini,[...]. ESC Heart Fail 2018
85
11

The effect of dapagliflozin treatment on epicardial adipose tissue volume.
Takao Sato, Yoshifusa Aizawa, Sho Yuasa, Shohei Kishi, Koichi Fuse, Satoshi Fujita, Yoshio Ikeda, Hitoshi Kitazawa, Minoru Takahashi, Masahito Sato,[...]. Cardiovasc Diabetol 2018
143
11

Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies.
Shang-Hung Chang, Lung-Sheng Wu, Meng-Jiun Chiou, Jia-Rou Liu, Kuang-Hui Yu, Chang-Fu Kuo, Ming-Shien Wen, Wei-Jan Chen, Yung-Hsin Yeh, Lai-Chu See. Cardiovasc Diabetol 2014
113
11

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.
James P Curtain, Kieran F Docherty, Pardeep S Jhund, Mark C Petrie, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine,[...]. Eur Heart J 2021
37
13

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
9

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Jason H Y Wu, Celine Foote, Juuso Blomster, Tadashi Toyama, Vlado Perkovic, Johan Sundström, Bruce Neal. Lancet Diabetes Endocrinol 2016
306
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.